Folic Acid-Modified Fe3O4@Au Core/shell Nanostars for Multimode Imaging and Photothermal Therapy of Tumors
Shi Xiangyang,Yong Hu,Wang Ruizhi,Shen Mingwu
DOI: https://doi.org/10.3389/conf.fbioe.2016.01.01648
IF: 5.7
2016-01-01
Frontiers in Bioengineering and Biotechnology
Abstract:Event Abstract Back to Event Folic acid-modified Fe3O4@Au core/shell nanostars for multimode imaging and photothermal therapy of tumors Xiangyang Shi1, Yong Hu1, Ruizhi Wang2 and Mingwu Shen1 1 Donghua University, College of Chemistry, Chemical Engineering and Biotechnology, China 2 Zhongshan Hospital, Fudan University,, Interventional Radiography, China Iron oxide (Fe3O4) nanoparticles (NPs) have been generally used as T2-negative magnetic resonance (MR) imaging contrast agents because of their ability to shorten the T2 relaxation time of water protons[1]. On the other hand, gold (Au) NPs have been widely used as CT imaging contrast agents due to their high X-ray attenuation coefficient[2]. In addition, AuNPs with particular shapes such as nanorods, nanocages, or nanostars (NSs) display strong surface plasmon resonance (SPR) absorption in near infrared (NIR) region, enabling their uses for photoacoustic (PA) imaging, thermal imaging and photothermal therapy of cancer[3],[4]. In this work, a facile mild reduction method was employed to synthesize Fe3O4@Ag nanoparticles (NPs)[1] and the thus-prepared NPs were used as seeds to form Fe3O4@Au NSs in the Au growth solution. Further sequential modification of polyethyleneimine (PEI) and folic acid (FA)-conjugated polyethylene glycol (PEG-FA) affords the NSs with excellent colloidal stability, good biocompatibility, and targeting specificity to cancer cells over-expressing FA receptors. With the Fe3O4 core NPs and the star-shaped Au shells, the formed Fe3O4@Au-PEI.Ac-PEG-FA NSs are able to be used as a nanoprobe for efficient of MR and computed tomography (CT) imaging of cancer cells in vitro and the xenografted tumor model in vivo. Likewise, the NIR absorption property enables the developed Fe3O4@Au-PEI.Ac-PEG-FA NSs to be used as a nanoprobe for PA and thermal imaging of tumors in vivo and photothermal ablation of cancer cells in vitro and the xenografted tumor model in vivo. This study fully demonstrates a unique multifunctional theranostic nanoplatform for multimode imaging and photothermal therapy of tumors. National Natural Science Foundation of China (21273032, 81341050, and 81371623); Sino-German Center for Research Promotion (GZ899); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Fundamental Research Funds for the Central Universities; Innovation Funds of Donghua University Master Dissertation of ExcellenceReferences:[1] Hu et al. Biomater. Sci., 2015, 3, 721[2] Peng et al. Biomaterials, 2012, 33, 1107-1119[3] Li et al. Biomaterials, 2015, 38, 10-21[4] Dinish et al. Adv. Funct. Mater., 2015, 25, 2316–2325 Keywords: MRI, contrast agent, theranostic, Nano/micro particle Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: New Frontier Oral Topic: Cell-targeting biomaterials in theranostic delivery Citation: Shi X, Hu Y, Wang R and Shen M (2016). Folic acid-modified Fe3O4@Au core/shell nanostars for multimode imaging and photothermal therapy of tumors. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.01648 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Xiangyang Shi Yong Hu Ruizhi Wang Mingwu Shen Google Xiangyang Shi Yong Hu Ruizhi Wang Mingwu Shen Google Scholar Xiangyang Shi Yong Hu Ruizhi Wang Mingwu Shen PubMed Xiangyang Shi Yong Hu Ruizhi Wang Mingwu Shen Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.